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The wide international variation in prostate cancer incidence, and
increased risks for men who migrate from low- to high-risk coun-
tries, provide indirect evidence for the existence of environmental
risk factors for prostate cancer (Nomura and Kolonel, 1991).
Dietary factors, particularly the consumption of fat, have been
identified as likely environmental risk factors for prostate cancer
(Kolonel, 1996; Giovannucci, 1995), but the underlying mecha-
nisms and specific dietary risk factors remain unclear. It has been
proposed that through competitive inhibition of cyclooxygenase
and lipoxygenase pathways, n-3 polyunsaturated fatty acids from
marine foods may modify the biosynthesis of arachidonic acid-
derived prostaglandins and other eicosanoids and thereby inhibit
prostate carcinogenesis or progression (Karmali, 1987).
Experimental studies involving the human prostate cancer cell
lines PC-3 and DU145 have shown inhibition of cell proliferation
rates with exposure to long-chain n-3 polyunsaturated fatty acids
including eicosapentaenoic acid (EPA, C20:5n-3) and docosa-
hexaenoic acid (DHA, C22:6n-3) (Rose, 1997). There have been
few human studies of the influence of dietary EPA and DHA on
prostate cancer risk since daily intake of these individual fatty
acids is relatively low in most Westernized countries, and valid
and reliable dietary assessment instruments have not been avail-
able with which to estimate their consumption. In order to address
these concerns, the current study aimed to investigate associations
between prostate cancer risk and EPA and DHA intake assessed
primarily by erythrocyte-based biomarker measurements.
MATERIALS AND METHODS
The study participants
The Auckland Prostate Study is a population based case–control
study which was carried out in the greater metropolitan area of
Auckland, New Zealand. The study population included all men
aged 40–80 years normally resident in the Auckland area during
the 13-month study recruitment period from January 1996. Almost
all men with newly diagnosed prostate cancer in this Auckland
population age group attend specialist urologists, either in one
public hospital-based clinic, or one of three private clinics
involving seven urologists. In this study, all public hospital
urology clinic attendees and patients attending five of seven
private clinic urologists were eligible for participation. In order to
improve response rates and reduce dietary assessment biases
arising from knowledge of a recent cancer diagnosis, the majority
of prostate cancer cases were recruited prospectively from a larger
group of urology clinic attendees prior to the completion of clinic
investigations for prostate cancer. The remainder of prostate
cancer cases in the study population were identified retrospec-
tively from histology reports, but within 3 weeks of the cancer
diagnosis. All prostate cancer cases were confirmed by reference
to histology reports. The study identified a sub-group of
‘advanced’ cancer cases who were men with clinically significant
disease. The definition of ‘advanced’ cancers was defined prior to
study analyses and was based upon tumour stage and grade. It
comprised cases with documented pathological or radiological
evidence of tumour invasion beyond the prostate capsule, or a
tumour with a combined Gleason score of seven or more.
Study controls comprised men aged 40–80 years, with no
history of prostate cancer, randomly selected from the general
electoral rolls (these provide 95% coverage of adult European men
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Correspondence to: AE Norrishin the Auckland region). Control participants were group-matched
to cases during the study recruitment period using 10-year age
groups and an approximate case–control ratio of 1:1.5. Approval
to carry out the study was obtained from the Northern Regional
Health Authority Ethics Committee and written consent was
obtained from all participants.
Collection of questionnaire data
Identical procedures were used for exposure data collection from
cases and controls. Study participants completed self-administered
questionnaires including a validated 107 food-item food frequency
questionnaire (Sharpe et al, 1993) and a general questionnaire
covering personal, socio-demographic, anthropometric, medical
and lifestyle data. Spearman correlation coefficients for estimated
intake of total fat and total polyunsaturated fat (food frequency
questionnaire vs 7-day food record) were 0.69 and 0.63 respec-
tively (Sharpe et al, 1993). Research nurses visited all participants
at home to obtain blood samples and to check the completeness of
responses to the questionnaires which had been posted to partici-
pants 1–2 weeks previously. Participants with missing responses
were encouraged to fully complete the questionnaires (self-admin-
istered) at the time of the visit. Although the nurse-interviewers
were not ‘blind’ to the case–control status of participants, neither
they nor the participants were aware of specific hypotheses
concerning diet and prostate cancer risk.
Blood sample processing and erythrocyte fatty acid
analysis
Ten millilitres of whole blood was collected from participants in
EDTA and transported promptly to the laboratory in chilled poly-
styrene containers. Erythrocytes were separated from plasma and
washed three times in HEPES-buffered saline. Centrifugation of
samples was carried out at 4°C. Washed erythrocyte samples were
transferred to cryovials (Greiner) allowing minimal headspace air
in each vial and stored at –82°C for a period of 3–12 months prior
to further analysis. Lipids were extracted from packed erythrocytes
according to the method of Bligh and Dyer (1959) and fatty acid
composition of erythrocyte phosphatidylcholine was determined
using gas-liquid chromatography, as described by Holub and Skeaff
(1987). The precision of the fatty acid measurement was deter-
mined by repeated analyses (n = 22) of a pooled erythrocyte sample
carried out over the analysis period. Coefficients of variation for
EPA and DHA were 7.3% and 8.2% respectively. The addition of
internal standard to sample and blank extractions permitted sample
peak areas to be corrected for background contamination.
Quantification of the area under the curves for individual fatty acids
allowed calculation of the molar proportion of the total fatty acids.
Laboratory staff were kept blind to the case–control status of
participants’ blood samples.
Statistical analysis
Nutrient consumption was estimated from the food frequency
questionnaire data and New Zealand food composition tables
(Burlingame et al, 1993). Categories of exposure for nutrients and
the molar percentage of erythrocyte fatty acids were defined by
quartiles, based upon the distribution in the control group. Relative
risks for total and advanced prostate cancers were calculated for
quartile categories, with the reference group comprised of the
lowest quartile. Since controls were matched to cases by age group
during recruitment, age-adjusted relative risks were calculated for
all analyses. Multivariate relative risks were calculated using an
unconditional logistic regression model. Age was included as a
continuous variable in regression models, but other co-variates
were included as categorical terms. Socio-economic status was
defined by the participants’ usual current or former occupation (if
retired), according to the modified Elley-Irving Classification
(Johnston, 1983) which has been widely used in New Zealand popu-
lation research. Energy-adjustment of fatty acid data was carried out
by including categorical terms for total energy consumption
(derived from the food frequency questionnaire) in the logistic
regression model. A test for overall trend across categories used the
P-values from a logistic regression model, which included ordinal
terms for each quartile of intake as well as confounding co-variates.
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Table 1 Characteristics of the study participants – controls and total prostate cancers
Characteristic Controls Total cases P-valuea
n = 480 n = 317
Age – mean years (s.e.m.) 69.1 (0.3) 68.3 (0.4) 0.10
Socio-economic status – numberb (%)
– high 211 (44) 98 (31)
– middle 114 (24) 85 (27)
– low 149 (31) 129 (41) 0.001
Non-steroidal anti-inflammatory drug treatmentc – number (%) 176 (37) 105 (33) 0.27
Total energy intake – mean kJ day–1 (s.e.m.) 8818 (117) 8929 (158) 0.57
Total fat intake – mean g day–1 (s.e.m.) 76.2 (1.3) 77.2 (1.7) 0.67
Total polyunsaturated fat intake – mean g day–1 (s.e.m.) 9.9 (0.2) 10.5 (0.3) 0.12
Total saturated fat intake – mean g day–1 (s.e.m.) 33.3 (0.7) 33.5 (0.9) 0.89
Total monounsaturated fat intake – mean g day–1 (s.e.m.) 24.9 (0.5) 25.0 (0.6) 0.86
Total eicosapentaenoic acid intake – mean g day–1 (s.e.m.)d 0.07 (0.004) 0.07 (0.004) 0.59
Total docosahexaenoic acid intake – mean g day–1 (s.e.m.)d 0.11 (0.006) 0.10 (0.006) 0.65
Lycopene intake – mean mg day–1 (s.e.m.) 1616 (80) 1428 (69) 0.08
Erythrocyte eicosapentaenoic acid – mean mol % (s.e.m.) 0.67 (0.02) 0.62 (0.02) 0.05
Erythrocyte docosahexaenoic acid intake – mean mol % (s.e.m.) 1.47 (0.02) 1.38 (0.03) 0.01
aP-value for the comparison of total cases versus controls. bTotal numbers may be incomplete due to missing data for some observations. cRegular use of
aspirin or other non-steroidal anti-inflammatory drugs. dEstimated daily intake based upon food frequency questionnaire data.RESULTS
Participants in the Auckland Prostate Study included a total of 317
prostate cancer cases (77% response rate) and 480 controls (71%
response rate). The results of blood sample analyses were avail-
able for 285 cases (90%) and 427 (89%) of study controls. Due to
the age-matched recruitment process there was little difference in
age distribution of cases and controls, however, cases were of
lower socio-economic status and less likely to receive regular
treatment with non-steroidal anti-inflammatory drugs (Table 1).
Energy and total fat intake was similar between the two groups,
but cases reported a lower mean intake of lycopene and had lower
erythrocyte levels of EPA and DHA. Examination of these charac-
teristics amongst participants for whom blood results were avail-
able revealed only very minor differences from the total study
population.
For the control group the Spearman coefficient (r) for the corre-
lations between erythrocyte phosphatidylcholine EPA measure-
ment and food frequency questionnaire-estimated daily intake of
total fish was 0.26; for DHA, Spearman r = 0.32. Similar correla-
tion coefficient values were observed for cases. A significant
inverse association was observed between erythrocyte measure-
ments of EPA and DHA and the risk of prostate cancer (Table 2).
This association persisted following adjustment for a number of
potential confounding variables included in a multivariate model.
Energy-adjusted analyses resulted in negligible differences in rela-
tive risk estimates and are not presented. However, estimates of
daily EPA and DHA intake derived from the food frequency ques-
tionnaire were not significantly associated with prostate cancer
risk; the multivariate relative risk for the upper quartile versus the
lowest quartile of EPA intake was 0.96 (95% confidence interval
(CI) 0.63–1.48); and for DHA intake the relative risk was 1.10
(95% CI 0.71–1.70).
DISCUSSION
This population-based case–control study of prostate cancer has
observed a reduction in prostate cancer risk associated with dietary
biomarker measurements of EPA and DHA intake, but not with
estimated dietary intakes of these fatty acids derived from self-
reported food consumption.
A major goal of our study was to incorporate more accurate
measurements of dietary exposure to fish oils. The molar propor-
tion of individual erythrocyte fatty acids quantified in our study
represents a relative measure of fatty acid exposure integrated over
time at the circulation level, closer to the target tissue of concern.
This approach reduces some of the uncertainties concerning self-
reported diets and nutritional database inadequacies. Several inter-
vention studies of human subjects given controlled diets of EPA
and DHA (including those with moderate intake levels) have
demonstrated clear associations with the erythrocyte fatty acid
composition of these fatty acids (Glatz et al, 1989; Agren and
Hanninen, 1991; Brown et al, 1991; Vajreswari and
Narayanareddy, 1992). Although not directly examined in erythro-
cytes, it has been demonstrated that the consumption of pre-
formed EPA and DHA in the diet leads to a greater increase of
these fatty acids in plasma and platelet phospholipids than an
equivalent intake of dietary alpha-linolenic acid (Sanders and
Roshanai, 1983; Mantzioris et al, 1994), suggesting that dietary
intake, rather than endogenous biosynthesis is the major determi-
nant of circulating levels in humans.
We observed only moderate correlations between erythrocyte
levels of EPA and DHA and self-reported fish intake, but similar
correlation values existed for prostate cancer cases and controls.
These findings are similar to those reported by a previous small
case–control study of prostate cancer (Godley et al, 1996a). They
suggest that the food frequency questionnaires used in these
studies may not constitute a very sensitive and accurate means of
assessing EPA and DHA intake, particularly in study populations
with relatively restricted intakes of marine food sources. However,
the similar correlations for prostate cancer cases and controls
provide indirect evidence that prostate cancer does not seriously
disrupt the relationship between dietary fatty acids and their incor-
poration into erythrocytes, an important theoretical concern with
the use of biological measurements of exposure in case–control
studies. Although differences in plasma fatty acids observed
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Table 2 Prostate cancer relative risk and eicosapentaenoic acid and docosahexaenoic acid levels in erythrocyte phosphatidylcholine, by quartile, total and
advanced cancers
Quartile – relative risk (95% confidence interval)
Fatty acid Q1 Q2 Q3 Q4 (high) P for trend
Eicosapentaenoic – mol %a < 0.44 0.44–0.62 0.62–0.83 > 0.83
acid (C20:5n-3) Total cancers:
– age-adjusted RR 1.00 0.65 (0.43–0.99) 0.70 (0.46–1.05) 0.60 (0.39–0.92) 0.02
– multivariate RRb 1.00 0.74 (0.47–1.14) 0.72 (0.46–1.12) 0.59 (0.37–0.95) 0.03
Advanced cancers:
– age-adjusted RR 1.00 0.66 (0.41–1.07) 0.68 (0.42–1.10) 0.57 (0.34–0.94) 0.03
– multivariate RRb 1.00 0.73 (0.43–1.22) 0.65 (0.38–1.11) 0.54 (0.31–0.96) 0.03
Docosahexaenoic – mol %a < 1.13 1.13–1.42 1.42–1.70 > 1.70
acid (C22:6n-3) Total cancers:
– age-adjusted RR 1.00 0.80 (0.53–1.20) 0.53 (0.34–0.83) 0.66 (0.43–1.00) 0.02
– multivariate RRb 1.00 0.83 (0.53–1.28) 0.54 (0.33–0.87) 0.62 (0.39–0.98) 0.01
Advanced cancers:
– age-adjusted RR 1.00 0.83 (0.52–1.32) 0.44 (0.26–0.76) 0.73 (0.45–1.18) 0.06
– multivariate RRb 1.00 0.84 (0.51–1.39) 0.46 (0.25–0.82) 0.66 (0.39–1.13) 0.04
aBased upon percentage of total peak areas. bMultivariate logistic regression model including terms for age, height, total non-steroidal anti-inflammatory drug
use, socio-economic status, and food frequency questionnaire-estimated intake of total polyunsaturated fat and lycopene.Prostate cancer risk and fish oil consumption 1241
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between colorectal cancer patients and controls have been attrib-
uted, at least in part, to metabolic changes associated with malig-
nancy, corresponding differences were not reported for erythrocyte
fatty acids in the same study (Baro et al, 1998).
The initial participant response rates are typical of those
achieved by this type of case–control study design; however,
incomplete recruitment raises the potential for selection bias in our
study. The excluded cases attending two out of seven private urol-
ogists were estimated to represent only 9% of the total number of
cases, and were expected to be representative of private cases
overall. While their exclusion may be expected to contribute to
differences in the socio-economic status of cases and controls, all
analyses were adjusted for this variable. By comparing the charac-
teristics of participants with available and missing erythrocyte
data, we ascertained that the availability of blood sample analyses
was unrelated to the exposure or disease status of participants, and
unlikely to result in selection bias. Since the majority of cases in
our study (60%) provided blood samples and questionnaire data
prior to their cancer diagnosis, or shortly after diagnosis in the
remainder (retrospectively recruited cases), the potential for bias
involving dietary recall or modification may be less than in tradi-
tional case–control study designs.
Few previous human prostate cancer studies have investigated
associations with marine foods or longer chain n-3 polyunsatu-
rated fatty acids due to dietary assessment limitations. Two
case–control studies involving Japanese and British men have
suggested that prostate cancer risk may be raised amongst men
who reported consuming little seafood in their diet (Mishina et al,
1985; Ewings and Bowie, 1996), but a cohort study conducted in
the USA observed no association with long-chain n-3 fat from fish
(Giovannucci et al, 1992), a result consistent with our own food
frequency questionnaire-derived findings. Only three previous
studies have incorporated dietary biomarkers. A small urology
clinic-based case–control study involving 89 cases and 38 controls
has reported a reduced prostate cancer risk associated with the
highest quartile of EPA and DHA levels in erythrocytes, but the
precision of relative risk estimates was low and there was no clear
gradient of risk over increasing levels of exposure (Godley et al,
1996b). No significant associations with EPA or DHA were noted
by two small prospective studies involving 120 cases and 35 cases
respectively (Gann et al, 1994; Harvei et al, 1997), which
measured fatty acids in stored serum and plasma samples collected
as part of earlier studies (these samples may provide a less valid
biomarker measurement of dietary fatty acid intake compared with
erythrocyte or adipose tissue samples collected specifically for this
purpose).
The underlying cellular and molecular processes by which fish
oils may reduce prostate cancer risk have not been established;
however, mechanisms involving the inhibition of cancer progres-
sion via modulation of arachidonic acid-derived eicosanoid
biosynthesis are plausible (Earnest et al, 1992; Lupulescu, 1996).
EPA and DHA have been shown to inhibit the augmented produc-
tion of PGE2 by malignant prostate tissue (Chaudry et al, 1994)
and cell proliferation rates in human prostate cancer cell lines in
vitro (Karmali, 1987; Rose and Connolly, 1991), although a more
recent experimental study demonstrated an inhibitory effect of
EPA only at high doses (Pandalai et al, 1996). Many of these
experimental studies have also demonstrated inhibition of prostate
cancer cell proliferation with non-steroidal anti-inflammatory
drugs (cyclooxygenase inhibitors) and a reduced risk of advanced
prostate cancer has been previously reported amongst men in our
study who regularly took non-steroidal anti-inflammatory drugs
(Norrish et al, 1998).
In conclusion, our observations of a reduced prostate cancer risk
associated with increased levels of long-chain n-3 polyunsaturated
fatty acids in erythrocytes are supportive of eicosanoid-based
hypotheses for prostate carcinogenesis or progression, and warrant
further investigation.
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